Current & Prospective Partners

Clinical Development Partners


PDS has a clinical trial collaboration with Merck to evaluate the combination of PDS’s PDS0101 with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in a Phase 2b clinical trial.

This trial will evaluate the safety and efficacy of the PDS0101-KEYTRUDA® combination in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection after failure with platinum-based chemotherapy.


PDS has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), an Institute of the U.S. National Institutes of Health. Under CRADA03039, PDS and NCI are co-developing several immunotherapies in upcoming Phase 2b clinical trials over the 2018–2021 period.

This partnership targets HPV-related cancers, prostate, and breast cancers.

The products will be owned by PDS Biotechnology (IND holder).

The confirmed initial CRADA03039-sponsored clinical trials include:

  • PDS0101: Phase 2b clinical trial in pre-anal (Anal Intraepithelial Neoplasia, or AIN2/3) patients who are also HIV-positive.
  • PDS0102: Phase 2b clinical trial in late-stage prostate cancer (Stage D0) patients at risk of biochemical recurrence without radiographically measurable disease.

Commercial Partners


Schaffhausen, Switzerland: A division of EMD-Millipore, Merck Cie, has developed a proprietary process to manufacture the patented structurally-specific lipid used in Versamune®. Merck Cie has granted PDS Biotechnology an exclusive worldwide commercial license to utilize the chiral lipid in immunotherapies and vaccines.  Merck Cie provides the lipid manufactured under cGMP conditions for use in PDS Biotechnology’s products.

New Partners

PDS welcomes additional partners to develop the Versamune®-based immunotherapies including combination immunotherapies.

Parties interested in collaborating with PDS to develop novel cancer immunotherapies should contact:

Telephone: (732) 640-0145

  • About Us

    PDS Biotechnology Corporation logo image

    PDS Biotechnology is a clinical stage biopharmaceutical company developing novel cancer immunotherapies and vaccines for infectious diseases.

  • Contact Us

    PDS Biotechnology Corporation
    Commercialization Center for Innovative Technologies (CCIT)

    675 US Highway One
    North Brunswick, NJ 08902

    Tel: 732-640-0145
    Fax: 732-640-0144